• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

    2/7/24 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email
    • Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
    • Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candidate Selection Targeted for 2024
    • Cash and Marketable Securities Totaled $337.2 Million at December 31, 2023

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.

    "In 2024, Enanta began a year which will be marked by execution and value creation across the company. We are preparing for multiple catalysts across our pipeline in 2024, starting with RSV, where we anticipate reporting topline data from the RSVPEDs Phase 2 study of zelicapavir, pending the continuation of a normal Northern Hemisphere RSV season, and the Phase 2a challenge study of EDP-323, in the third quarter of this year," said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. "Beyond RSV, we are excited to leverage our experience in virology and expertise in small molecule drug discovery to develop a robust immunology program, starting with our first program of KIT inhibitors for the treatment of chronic spontaneous urticaria (CSU), a severely debilitating, chronic inflammatory skin disease. We are driven to help the millions of patients impacted by CSU and potentially other mast-cell-driven indications. Furthermore, we plan to expand more broadly into immune-mediated chronic diseases with high unmet need, with the announcement of a second program in 2024. To that end, we will continue to innovate and strengthen our pipeline, sustained by a solid cash position that will support the company well beyond a catalyst-rich 2024."

    Fiscal First Quarter Ended December 31, 2023 Financial Results

    Total revenue for the three months ended December 31, 2023 was $18.0 million and consisted of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®, AbbVie's eight-week treatment for chronic hepatitis C virus (HCV). For the three months ended December 31, 2022, total revenue was $23.6 million and was primarily related to royalties on AbbVie's sales of MAVYRET®/MAVIRET®.

    Beginning with the quarter ended September 30, 2023, 54.5% of Enanta's ongoing royalties from AbbVie's net sales of MAVYRET®/MAVIRET® are being paid to OMERS, one of Canada's largest defined benefit pension plans, pursuant to a royalty sale transaction in April 2023. For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Enanta will continue to record 100% of the royalty earned as revenue and will then amortize the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS, until a cap of 1.42 times the purchase payment is met, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense from the royalty sale was $3.4 million for the three months ended December 31, 2023.

    Research and development expenses totaled $36.4 million for the three months ended December 31, 2023, compared to $40.9 million for the three months ended December 31, 2022. The decrease was primarily due to a decrease in costs associated with Enanta's COVID-19 program, as the company announced previously that plans to pursue any future COVID-19 efforts would be in the context of a collaboration.

    General and administrative expenses totaled $16.5 million for the three months ended December 31, 2023, compared to $12.7 million for the three months ended December 31, 2022. This increase was due to an increase in stock compensation expense and an increase in legal fees related to the company's patent infringement suit against Pfizer.

    Enanta recorded an income tax benefit of $0.6 million for the three months ended December 31, 2023, for interest earned on a pending $28 million federal income tax refund, compared to an income tax benefit of less than $0.1 million for the three months ended December 31, 2022.

    Net loss for the three months ended December 31, 2023 was $33.4 million, or a loss of $1.58 per diluted common share, compared to a net loss of $29.0 million, or a loss of $1.39 per diluted common share, for the corresponding period in 2022.

    Enanta's cash, cash equivalents and short-term marketable securities totaled $337.2 million at December 31, 2023. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs through fiscal year 2027.

    Virology

    Respiratory Syncytial Virus (RSV)

    • Enanta aims to develop a first and leading RSV antiviral treatment portfolio to help all populations at high risk for severe outcomes from RSV. This currently includes zelicapavir, Enanta's lead, oral, N-protein inhibitor (formerly known as EDP-938), which is being evaluated in two ongoing Phase 2 studies, RSVPEDs and RSVHR, and EDP-323, an oral, L-protein inhibitor.
      • RSVPEDs is a Phase 2, randomized, double-blind, placebo-controlled study of zelicapavir in hospitalized and non-hospitalized pediatric RSV patients.
      • RSVHR is a Phase 2b, randomized, double-blind, placebo-controlled study of zelicapavir in adults with RSV infection who are at high risk of complications, including the elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease or asthma.
      • Based on current enrollment trends, Enanta anticipates reporting data from RSVPEDs in the third quarter of 2024, if this winter continues to be a more normal RSV season in the Northern Hemisphere. The Company will provide additional guidance on the RSVHR study as the season continues.
    • Enanta's second RSV candidate EDP-323 is on track to report topline data from its ongoing Phase 2a challenge study in the third quarter of 2024. In this randomized, double-blind, placebo-controlled, human challenge study the safety, pharmacokinetics (PK), and changes in viral load measurements and symptoms will be evaluated in up to 114 healthy adult subjects who will be infected with RSV. EDP-323 is supported by Phase 1 data which demonstrated favorable safety, tolerability, and PK indicative of once-daily dosing, with high exposure multiples.

    Immunology

    Chronic Spontaneous Urticaria (CSU)

    • In January, Enanta announced its expansion into immunology with a first program focused on KIT inhibitors for the treatment of CSU, a severely debilitating, chronic inflammatory skin disease characterized by hives, with limited effective oral treatment options. The company aims to address the significant unmet need in CSU by developing a best-in-disease, oral KIT inhibitor treatment to reduce the number of mast cells, which are the primary driver of the disease. As mast cells are implicated in multiple allergic diseases, this approach will allow for follow-on programs in other immunology indications.
    • Enanta's prototype oral inhibitors exhibit potent inhibition of KIT in binding and cellular functional assays, are highly selective for KIT versus other kinases and demonstrate good in vitro and in vivo ADME properties. Preclinical optimization of Enanta's potent and selective oral KIT inhibitors is ongoing and the company is targeting a development candidate selection in late 2024, as well as plans to introduce a second immunology program in 2024.

    Upcoming Events

    • Oppenheimer 34th Annual Healthcare Life Sciences Conference, February 13, 2024
    • Leerink Global Biopharma Conference 2024, March 13, 2024
    • Enanta plans to issue its fiscal second quarter financial results press release, and hold a conference call regarding those results, on May 6, 2024.

    Conference Call and Webcast Information

    Enanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To participate by phone, please register for the call here. It is recommended that participants register a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta's website for approximately 30 days following the event.

    About Enanta Pharmaceuticals, Inc.

    Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

    Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit www.enanta.com for more information.

    Forward Looking Statements

    This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta's clinical programs in RSV and its preclinical program in CSU. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV and CSU; the discovery and development risks of Enanta's programs in RSV and CSU; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; Enanta's lack of clinical development experience; Enanta's need to attract and retain senior management and key research and development personnel; Enanta's need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in "Risk Factors" in Enanta's Form 10-K for the fiscal year ended September 30, 2023, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

    Tables to Follow

    ENANTA PHARMACEUTICALS, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    UNAUDITED

    (in thousands, except per share amounts)
     
    Three Months Ended
    December 31,

    2023

    2022

     
    Revenue

    $

    18,003

     

    $

    23,585

     

    Operating expenses
    Research and development

     

    36,371

     

     

    40,902

     

    General and administrative

     

    16,518

     

     

    12,696

     

    Total operating expenses

     

    52,889

     

     

    53,598

     

    Loss from operations

     

    (34,886

    )

     

    (30,013

    )

    Interest expense

     

    (3,441

    )

     

    —

     

    Interest and investment income, net

     

    4,298

     

     

    993

     

    Loss before income taxes

     

    (34,029

    )

     

    (29,020

    )

    Income tax benefit

     

    622

     

     

    34

     

    Net loss

    $

    (33,407

    )

    $

    (28,986

    )

    Net loss per share
    Basic

    $

    (1.58

    )

    $

    (1.39

    )

    Diluted

    $

    (1.58

    )

    $

    (1.39

    )

    Weighted average common shares outstanding
    Basic

     

    21,088

     

     

    20,816

     

    Diluted

     

    21,088

     

     

    20,816

     

    ENANTA PHARMACEUTICALS, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    UNAUDITED

    (in thousands)
     

    December 31,

     

    September 30,

    2023

     

    2023

    Assets
    Current assets
    Cash and cash equivalents

    $

    39,933

     

    $

    85,388

     

    Short-term marketable securities

     

    297,218

     

     

    284,522

     

    Accounts receivable

     

    8,173

     

     

    8,614

     

    Prepaid expenses and other current assets

     

    13,245

     

     

    13,263

     

    Income tax receivable

     

    31,734

     

     

    31,004

     

    Total current assets

     

    390,303

     

     

    422,791

     

    Property and equipment, net

     

    12,119

     

     

    11,919

     

    Operating lease, right-of-use assets

     

    21,344

     

     

    22,794

     

    Restricted cash

     

    3,968

     

     

    3,968

     

    Other long-term assets

     

    765

     

    803

    Total assets

    $

    428,499

     

    $

    462,275

     

    Liabilities and Stockholders' Equity
    Current liabilities
    Accounts payable

    $

    9,326

     

    $

    4,097

     

    Accrued expenses and other current liabilities

     

    11,603

     

     

    18,339

     

    Liability related to the sale of future royalties

     

    36,512

     

     

    35,076

     

    Operating lease liabilities

     

    4,966

     

     

    5,275

     

    Total current liabilities

     

    62,407

     

     

    62,787

     

    Liability related to the sale of future royalties, net of current portion

     

    151,612

     

     

    159,429

     

    Operating lease liabilities, net of current portion

     

    20,524

     

     

    21,238

     

    Series 1 nonconvertible preferred stock

     

    1,423

     

     

    1,423

     

    Other long-term liabilities

     

    649

     

     

    663

     

    Total liabilities

     

    236,615

     

     

    245,540

     

    Total stockholders' equity

     

    191,884

     

     

    216,735

     

    Total liabilities and stockholders' equity

    $

    428,499

     

    $

    462,275

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240207046844/en/

    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    2/9/2022$80.00 → $68.00Market Perform
    SVB Leerink
    1/13/2022$85.00 → $80.00Market Perform
    SVB Leerink
    11/24/2021$55.00 → $73.00Perform
    Oppenheimer
    More analyst ratings

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vance Terry

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:44:01 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Russell Lesley

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:30 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peterson Kristine

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

      MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis If Left Untreated, Patients with Acute HCV Could Progress to Chronic Disease, Including Cirrhosis or Liver Cancer2 Glecaprevir, One of the Two Direct-Acting Antivirals in MAVYRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunologica

      6/11/25 12:34:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals

      5/27/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online. The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N

      5/22/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      2/12/25 8:09:35 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    SEC Filings

    See more
    • SEC Form S-8 filed by Enanta Pharmaceuticals Inc.

      S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:41:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.

      10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:00:25 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/12/25 4:05:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

      JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

      8/9/23 7:32:28 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

      8/8/23 6:35:35 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enanta Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00

      12/9/22 7:40:58 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

      4/30/24 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

      8/8/22 4:00:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

      WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

      1/26/21 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Financials

    Live finance-specific insights

    See more
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

      Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8 Million Federal Income Tax Refund Received in April 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results f

      5/12/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

      On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

      2/10/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

      Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and webcast to discuss data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from

      12/9/24 6:30:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      11/14/24 4:03:02 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      10/17/24 4:31:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      2/14/24 2:26:49 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care